2020 Guide to Patient Support Services

Teva Oncology

  • Teva Comprehensive Oncology Reimbursement Expertise
  • 888-587-3263
  • VISIT WEBSITE
  • Teva Cares Foundation Patient Assistance Program
  • 877-237-4881
  • VISIT WEBSITE

Teva Oncology offers access to oncology medications from Teva through Teva Comprehensive Oncology Reimbursement Expertise (CORE) and the Teva Cares Foundation Patient Assistance Program.

The complete list of oncology drugs from Teva Oncology, their indications, and available programs is provided in the Table.

TEVA CORE

Teva CORE is designed to provide a reimbursement support program and online tools and resources for oncology medications from Teva Oncology.

Teva CORE can provide assistance with benefit verification, coverage determination, prior authorizations, and letters of medical necessity, as well as personalized support throughout the claims and appeals processes.

For uninsured patients, Teva CORE can identify additional resources to assist patients with the costs of their treatment.

Teva Cares Foundation

Teva Cares Foundation Patient Assistance Program provides oncology medications at no cost to eligible patients who meet certain income and insurance criteria.

ELIGIBILITY

Teva CORE

Patients may qualify for assistance through Teva CORE if they:

  • Have been prescribed an oncology medication from Teva Oncology, including Bendeka (bendamustine hydrochloride), Granix (tbo-filgrastim), Synribo (omacetaxine mepesuccinate), Treanda (bendamustine hydrochloride), Trisenox (arsenic trioxide), or Truxima (rituximab-abbs)
  • Meet the annual household income requirements.

For more information about eligibility requirements, call 888-587-3263.

Teva Cares Foundation Patient Assistance Program

Patients may qualify for the Teva Cares Foundation Patient Assistance Program if they:

  • Are a US resident
  • Have been prescribed an oncology medication from Teva Oncology
  • Do not have prescription drug coverage
  • Meet the annual household income requirements.

More information about eligibility requirements can be found online or by calling 877-237-4881.

APPLICATION & ENROLLMENT

Teva CORE

Patients and prescribers must coordinate to complete their designated sections of the application.

Prescribers enrolling in the Teva CORE program can fill out a standard application form or can submit the form online through assistPoint provides oncology practices with the ability to register patients electronically to more efficiently access Teva CORE services.

Teva Cares Foundation Patient Assistance Program

Drug-specific application forms are available online for the Teva Cares Foundation Patient Assistance Program, and for the Teva CORE program.

The forms must be completed and faxed to the number on the enrollment form, or mailed directly to the program’s address listed on the form.

Proof of income is required from all sources and for all household members, as well as a prescription for an improved indication (if required).

TABLE TEVA ONCOLOGY/SUPPORTIVE CARE DRUGS

Drugs
Indications
Patient support programs

Drug
Bendeka (bendamustine hydrochloride)
Indications
Treatment of CLL; treatment of indolent B-cell NHL progressing during/within 6 months of rituximab or a rituximab-containing regimen
Patient support programs

Drug
Granix (tbo-filgrastim)
Indications
To reduce severe neutropenia in patients aged ≥1 months with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with febrile neutropenia
Patient support programs

Drug
Synribo (omacetaxine mepesuccinate)
Indications
Treatment of adults with chronic- or accelerated-phase chronic myeloid leukemia and resistance or intolerance to ≥2 tyrosine kinase inhibitors
Patient support programs

Drug
Treanda (bendamustine hydrochloride)
Indications
Treatment of CLL; treatment of indolent B-cell NHL that progressed during/within 6 months of rituximab or a rituximab-containing regimen
Patient support programs

Drug
Trisenox (arsenic trioxide)
Indications
First-line treatment of adults with low-risk APL characterized by t(15;17) translocation or PML/RAR-alpha gene expression, in combination with tretinoin; treatment of APL characterized by t(15;17) translocation or PML/RAR-alpha gene expression, and is refractory to, or relapsed after, retinoid and anthracycline chemotherapy
Patient support programs

Drug
Truxima (rituximab-abbs)
Indications
Treatment of relapsed/refractory, low-grade or follicular NHL; first-line treatment of follicular NHL, in combination with first-line chemotherapy; treatment of low-grade NHL, after first-line chemotherapy; first-line treatment of diffuse large B-cell NHL, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone, or with other anthracycline-based chemotherapy regimens; treatment of CLL, including first-line, in combination with fludarabine and cyclophosphamide
Patient support programs

APL indicates acute promyelocytic leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: